CA2843960C - Antibodies binding to phosphorylcholine (pc) and/or pc conjugates - Google Patents

Antibodies binding to phosphorylcholine (pc) and/or pc conjugates Download PDF

Info

Publication number
CA2843960C
CA2843960C CA2843960A CA2843960A CA2843960C CA 2843960 C CA2843960 C CA 2843960C CA 2843960 A CA2843960 A CA 2843960A CA 2843960 A CA2843960 A CA 2843960A CA 2843960 C CA2843960 C CA 2843960C
Authority
CA
Canada
Prior art keywords
antibody
sequence
seq
amino acid
antibody fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2843960A
Other languages
English (en)
French (fr)
Other versions
CA2843960A1 (en
Inventor
Knut Pettersson
Ola Camber
Dan SEXTON
Andrew E. Nixon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Athera Biotechnologies AB
Dyax Corp
Original Assignee
Athera Biotechnologies AB
Dyax Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Athera Biotechnologies AB, Dyax Corp filed Critical Athera Biotechnologies AB
Publication of CA2843960A1 publication Critical patent/CA2843960A1/en
Application granted granted Critical
Publication of CA2843960C publication Critical patent/CA2843960C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA2843960A 2011-08-09 2012-08-08 Antibodies binding to phosphorylcholine (pc) and/or pc conjugates Expired - Fee Related CA2843960C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161521607P 2011-08-09 2011-08-09
US61/521,607 2011-08-09
PCT/US2012/049990 WO2013022968A1 (en) 2011-08-09 2012-08-08 Antibodies binding to phosphorylcholine (pc) and/or pc conjugates

Publications (2)

Publication Number Publication Date
CA2843960A1 CA2843960A1 (en) 2013-02-14
CA2843960C true CA2843960C (en) 2020-09-15

Family

ID=47668922

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2843960A Expired - Fee Related CA2843960C (en) 2011-08-09 2012-08-08 Antibodies binding to phosphorylcholine (pc) and/or pc conjugates

Country Status (7)

Country Link
US (3) US9796786B2 (cg-RX-API-DMAC7.html)
EP (1) EP2741770A4 (cg-RX-API-DMAC7.html)
JP (1) JP6277126B2 (cg-RX-API-DMAC7.html)
CN (1) CN103906532B (cg-RX-API-DMAC7.html)
AU (1) AU2012294431B2 (cg-RX-API-DMAC7.html)
CA (1) CA2843960C (cg-RX-API-DMAC7.html)
WO (1) WO2013022968A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX364425B (es) 2011-08-09 2019-04-25 Athera Biotechnologies Ab Star Nuevos anticuerpos contra fosforilcolina.
AU2012294431B2 (en) * 2011-08-09 2017-03-30 Athera Biotechnologies Ab Antibodies binding to phosphorylcholine (PC) and/or PC conjugates
US20150376268A1 (en) * 2013-02-25 2015-12-31 The Regents Of The University Of California Antibodies to oxidized phospholipids
US20160208018A1 (en) 2015-01-16 2016-07-21 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for ror1
AU2017213844A1 (en) 2016-02-02 2018-08-02 Fred Hutchinson Cancer Center Anti-ROR1 antibodies and uses thereof
WO2024194686A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2402664A1 (fr) 1977-09-07 1979-04-06 Agronomique Inst Nat Rech Produits de couplage phosphorylcholine, composes amines procede d'obtention et applications
US5955584A (en) 1986-03-31 1999-09-21 Charter Ventures Atherosclerotic plaque specific antigens, antibodies thereto, and uses thereof
ES2070820T3 (es) 1986-08-06 1995-06-16 Scripps Clinic Res Anticuerpos monoclonales especificos de la apolipoproteina b, producidos por dos nuevos hibridomas.
JPH02188532A (ja) 1989-01-17 1990-07-24 Otsuka Pharmaceut Co Ltd リポソームワクチン
WO1990012632A1 (en) 1989-04-19 1990-11-01 The United States Of America, Represented By The Secretary, United States Department Of Commerce Process for removing c-reactive protein and anti-phosphorylcholine antibodies from biological fluids
JP3283041B2 (ja) 1990-07-13 2002-05-20 学校法人藤田学園 人工抗体
WO1992010203A1 (en) 1990-12-10 1992-06-25 Alving Carl R A vaccine against cholesterol to prevent hypercholesterolemia and atherosclerosis
CA2131150A1 (en) 1992-03-03 1993-09-16 Michel C. Nussenzweig Receptor complexes with b29 (ig-beta or ig-gamma) and their uses
AU5959494A (en) 1992-12-29 1994-07-19 Entremed, Inc Vaccines against sterols
WO1994018955A1 (en) 1993-02-22 1994-09-01 Alza Corporation Compositions for oral delivery of active agents
US5455032A (en) 1993-07-29 1995-10-03 The United States Of America As Represented By The Department Of Health And Human Services Use of phosphocholine hapten conjugates in vaccines
WO1998021581A1 (en) 1996-11-08 1998-05-22 The Regents Of The University Of California Methods and reagents for non-invasive imaging of atherosclerotic plaque
US6375925B1 (en) 1996-11-08 2002-04-23 The Regents Of The University Of California Methods and reagents for non-invasive imaging of atherosclerotic plaque
US6225070B1 (en) 1997-08-07 2001-05-01 The Regents Of The University Of California Antibodies to oxidation-specific epitopes on lipoprotein and methods for their use in detecting, monitoring and inhibiting the growth of atheroma
US20040185039A1 (en) 2002-08-30 2004-09-23 Heinz Kohler Therapeutic applications of noncovalent dimerizing antibodies
US6300308B1 (en) 1997-12-31 2001-10-09 Board Of Regents, The University Of Texas System Methods and compositions for inducing autoimmunity in the treatment of cancers
SE9802402D0 (sv) 1998-07-03 1998-07-03 Karolinska Innovations Ab Method of diagnosing cardiovascular disease and early atherosclerosis
DE69911417T2 (de) 1998-07-03 2004-06-17 Athera Biotechnologies Ab Verfahren zur diagnose von gefässerkrankungen und früher atheriosklerose
EP1224461B1 (en) 1999-10-26 2011-04-20 The Regents of The University of California Reagents and methods for diagnosing, imaging and treating atherosclerotic disease
SE0000855D0 (sv) 2000-03-15 2000-03-15 Karolinska Innovations Ab Antigenic composition useful as a vaccine against atherosclerosis
WO2001088547A2 (en) 2000-05-12 2001-11-22 The Regents Of The University Of California Standardized oxidized ldl assay
NZ522700A (en) * 2000-06-16 2006-02-24 Human Genome Sciences Inc Antibodies that immunospecifically bind to blys
DE10041515A1 (de) 2000-08-24 2002-03-14 Gerold Schuler Verfahren zur Herstellung gebrauchsfertiger, Antigen-beladener oder -unbeladener, kryokonservierter reifer dendritischer Zellen
US6838452B2 (en) 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
SE0103754L (sv) 2001-04-05 2002-10-06 Forskarpatent I Syd Ab Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid
US20070122419A1 (en) 2003-04-11 2007-05-31 The Regents Of The University Of California Methods and compositions for treating atherosclerosis
PL1735349T3 (pl) * 2004-04-15 2011-03-31 Athera Biotechnologies Ab Sposób oceny ryzyka niedokrwiennego schorzenia układu sercowo-naczyniowego za pomocą koniugatów fosforylocholiny
JP2008515774A (ja) * 2004-08-03 2008-05-15 ダイアックス コーポレイション ｈＫ１結合タンパク質
WO2006028162A1 (ja) 2004-09-08 2006-03-16 Eisai R & D Management Co., Ltd. シグナルプローブポリマーの形成方法
NZ561218A (en) * 2005-02-07 2011-04-29 Univ California Methods for reducing the symptoms of autoimmunity and inflammation using binding proteins against antigens exposed on dead or dying cells
AU2006235507B2 (en) * 2005-04-12 2012-08-30 Duke University Method of inducing neutralizing antibodies to human immunodeficiency virus
WO2007076200A2 (en) 2005-11-28 2007-07-05 Medimmune, Inc. Antagonists of hmgb1 and/or rage and methods of use thereof
US20090258005A1 (en) * 2007-05-29 2009-10-15 Trubion Pharmaceuticals Inc. Therapeutic compositions and methods
JP5122908B2 (ja) 2007-10-17 2013-01-16 日泉化学株式会社 自動車の内装用部材の取り付け構造
WO2010003602A1 (en) * 2008-07-07 2010-01-14 Athera Biotechnologies Ab New therapeutic and diagnostic methods for alzheimer's disease
EP2331574A2 (en) * 2008-09-05 2011-06-15 The Regents of The University of California Antibodies with mannose binding lectin effector function for inhibiting pathologic inflammatory conditions
WO2012010291A1 (en) 2010-07-21 2012-01-26 Athera Biotechnologies Ab Diagnostic and therapeutic methods and compositions for metabolic disease
JP2014506257A (ja) 2011-01-06 2014-03-13 ダイアックス コーポレーション 血漿カリクレイン結合タンパク質
AU2012294431B2 (en) * 2011-08-09 2017-03-30 Athera Biotechnologies Ab Antibodies binding to phosphorylcholine (PC) and/or PC conjugates
MX364425B (es) 2011-08-09 2019-04-25 Athera Biotechnologies Ab Star Nuevos anticuerpos contra fosforilcolina.

Also Published As

Publication number Publication date
JP6277126B2 (ja) 2018-02-07
JP2014529398A (ja) 2014-11-13
AU2012294431B2 (en) 2017-03-30
HK1199409A1 (en) 2015-07-03
US20140193413A1 (en) 2014-07-10
WO2013022968A1 (en) 2013-02-14
US20210230310A1 (en) 2021-07-29
EP2741770A4 (en) 2014-12-31
US20180086847A1 (en) 2018-03-29
CA2843960A1 (en) 2013-02-14
AU2012294431A1 (en) 2014-02-20
CN103906532B (zh) 2018-01-26
CN103906532A (zh) 2014-07-02
US9796786B2 (en) 2017-10-24
EP2741770A1 (en) 2014-06-18

Similar Documents

Publication Publication Date Title
JP6669800B2 (ja) Ｍａｓｐ−２依存性の補体活性化を阻害するための組成物
US20210238311A1 (en) Antibodies against phosphorylcholine
US20210230310A1 (en) Antibodies binding to phosphorylcholine (pc) and/or pc conjugates
JP2014530188A (ja) Ｐｃｓｋ９に対する抗体およびその使用
JP2016537406A (ja) システイニルロイコトリエン（ｃｙｓＬＴ）との結合のための疾病治療用組成物およびその方法
HK1199409B (en) Antibodies binding to phosphorylcholine (pc) and/or pc conjugates

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170227

MKLA Lapsed

Effective date: 20210809